Dixon Mitchell Investment Counsel Inc. Has $33.73 Million Stock Position in Danaher Co. (NYSE:DHR)

Dixon Mitchell Investment Counsel Inc. boosted its holdings in shares of Danaher Co. (NYSE:DHR) by 11.7% in the 4th quarter, Holdings Channel reports. The firm owned 146,781 shares of the conglomerate’s stock after buying an additional 15,341 shares during the period. Danaher accounts for about 1.6% of Dixon Mitchell Investment Counsel Inc.’s holdings, making the stock its 25th largest position. Dixon Mitchell Investment Counsel Inc.’s holdings in Danaher were worth $33,733,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Coronation Fund Managers Ltd. increased its holdings in shares of Danaher by 29.9% during the second quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock worth $1,596,000 after buying an additional 1,470 shares in the last quarter. Moors & Cabot Inc. grew its position in Danaher by 14.0% during the 2nd quarter. Moors & Cabot Inc. now owns 2,540 shares of the conglomerate’s stock worth $635,000 after acquiring an additional 311 shares during the last quarter. Primecap Management Co. CA increased its holdings in Danaher by 3.4% in the 2nd quarter. Primecap Management Co. CA now owns 66,937 shares of the conglomerate’s stock worth $16,724,000 after purchasing an additional 2,200 shares in the last quarter. Bradley Foster & Sargent Inc. CT raised its position in Danaher by 0.7% in the second quarter. Bradley Foster & Sargent Inc. CT now owns 553,940 shares of the conglomerate’s stock valued at $138,402,000 after purchasing an additional 3,916 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its stake in shares of Danaher by 12.2% during the second quarter. E Fund Management Co. Ltd. now owns 10,464 shares of the conglomerate’s stock valued at $2,614,000 after purchasing an additional 1,136 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 0.1 %

DHR opened at $237.78 on Thursday. The company has a fifty day moving average price of $235.27 and a two-hundred day moving average price of $253.56. Danaher Co. has a 1-year low of $222.53 and a 1-year high of $281.70. The company has a market cap of $171.74 billion, a P/E ratio of 45.38, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s revenue was up 3.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.02 EPS. Analysts predict that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is currently 20.61%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. TD Cowen raised their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus lifted their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Barclays decreased their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Finally, Guggenheim initiated coverage on Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.